Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Airway mucus mucopolysaccharides, now scientifically recognized as airway glycosaminoglycans (GAGs), are complex, long-chain polysaccharides that are integral components of the respiratory tract's protective mucus layer (PubMed, PMID: 15104163). These molecules, which include}
Reduction of mucus viscosity and enhancement of mucociliary clearance through the disruption of disulfide bonds in mucins, enzymatic degradation of DNA and polysaccharides, or osmotic hydration of the glycosaminoglycan-rich mucus matrix.
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Airway mucus glycosaminoglycans (GAGs).